Review Article
Systematic Review of Compound Danshen Dropping Pill: A Chinese Patent Medicine for Acute Myocardial Infarction
Table 4
GRADE analysis: summary of findings for the main comparison.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio; GRADE Working Group grades of evidence: High quality: further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: we are very uncertain about the estimate. 1One study had selective reporting. For the other studies, the overall risk of bias was felt to be unclear. 295%CI includes possibility of both benefits and harms, and the sample size was not the optimal information size. After sensitive analysis excluding the lower quality study, the result suggested benefit, but the sample size was still small. 3The overall risk of bias of the studies was unclear. The sample size was not the optimal information size. 495%CI included only benefit, so we were cautious about downgrading the imprecision although the sample size was less than the optimal information size. 5Unclear risk of bias and only 146 patients enrolled. 95%CI included possibility of both benefits and harms. 6The heterogeneity ( = 61%) can be explained by the major differences of conventional therapy and sample size between the two studies, and this outcome is not so important to affect the decision-making; therefore, we did not downgrade for this factor. 795%CI suggested benefit as well as no benefit. 8This is an indirect outcome for AMI patients. 9Final measurements at the end of the study. |